Osimertinib instructions in Chinese

Indications:

1.Epidermal Growth Factor Receptor(EGFR)No. 19< Adult patients with exon deletion or exon 21 L858R mutation are treated with adjuvant therapy for non-small cell lung cancer (non-small cell lung cancer) after tumor resection.

2.First-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor EGFRexon19 deletions or exon21 L858R mutations.

3.With pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFRexon19deletion or exon21 L858Rmutation, as detected by FDAapproved tests.

4.MetastaticEGFR as tested by FDA-approved test Treatment of adult patients with T790M mutation-positive non-small cell lung cancer whose disease has progressed during or after treatment with an EGFR tyrosine kinase inhibitor (TKI).

Mechanism of action:

The mechanism of action of osimertinib is mainly reflected in the inhibition of epidermal growth factor receptor (EGFR). It is a third-generation EGFR tyrosine kinase inhibitor that can specifically bind to EGFR, especially EGFR with the t790m mutation. Osimertinib competitively binds to the ATP binding site of EGFR, thereby inhibiting the autophosphorylation of EGFR and the transduction of downstream signals, thereby blocking the proliferation, growth and metastasis of tumor cells.

Osimertinib forSome specific mutants of EGFR, such as exon19 deletion typeEGFR, L858R/T790M EGFR, has significant inhibitory effects, making it an effective drug for the treatment of advanced non-small cell lung cancer, especially for patients who have developed resistance to other EGFR inhibitors.

Medication method:

Once a day, each time80mg.

Side effects:

1.Digestive tract symptoms: Patients taking osimertinib may experience nausea, vomiting, diarrhea and other symptoms. These reactions may affect the patient's appetite and digestive function. Diarrhea is a common gastrointestinal side effect, which may lead to increased stool frequency and abnormal stool shape.

2.Skin reactions: including rash, dry skin, paronychia, and oral mucositis. These skin reactions may cause discomfort and itching to patients, and in severe cases, skin inflammation may occur.

3.Interstitial lung disease: Some patients taking osimertinib may develop symptoms of interstitial lung disease such as cough and dyspnea. This is a serious side effect that requires prompt medical attention and targeted treatment.

4.Heart problems: Osimertinib may also cause heart diseases such as arrhythmias, abnormal left ventricular ejection fraction, and symptomatic congestive heart failure. These side effects may pose a threat to the patient's life and health and therefore require timely monitoring and treatment.

5. Osimertinib may also cause blood system side effects such as thrombocytopenia and white blood cell count, as well as eye discomfort such as blurred vision and cataracts.

Warnings and precautions:

During the period of medication, patients need to have liver function, electrocardiogram, heart function and electrolytes checked regularly in order to detect and deal with possible abnormalities in a timely manner.

Drug interactions:

Osimertinib interacts with certain drugs such as St. John's wort, rifampicin, phenytoin, etc. Special attention should be paid when using it and avoid taking it at the same time.

Medication for special populations:

Pregnant and breastfeeding women should avoid using osimertinib because it may cause harm to the fetus or infant. At the same time, patients with congenital longQTinterval syndrome should also avoid using this drug.